samedan logo
 
 
 
spacer
home > ebr > summer 2003 > biopharmaceutical characterisation - considering key questions
PUBLICATIONS
European Biopharmaceutical Review

Biopharmaceutical Characterisation - Considering Key Questions

In the race to bring new biotech derived products to market, researchers face many obstacles along the road from discovery to commercial success. So, any new analytical techniques which can help smooth the path, particularly through the regulatory approval stages, are always welcome. One such breakthrough has been the use of mass spectrometry (MS) to provide information about the primary protein and carbohydrate structure of biomolecules. MS techniques are now being applied routinely to the characterisation of products ranging in size and complexity from small synthetic peptides to conjugated antibody molecules. However, with the bewildering array of modern analytical instruments available, it is sometimes difficult to choose the most suitable strategies to use for a particular characterisation problem, or indeed decide if or when these studies should be performed. This article intends to address some of the frequently asked questions about biopharmaceutical characterisation using mass spectrometry.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Fiona M Greer, Director, Biochemical Services at M-Scan Ltd

Following a PhD in Protein Biochemistry from Aberdeen University, Fiona Greer joined M-Scan in 1984 to develop analytical services using the then new techniques of biopolymer mass spectrometry. She is Director of Biochemistry and VP of M-Scan Ltd, M-Scan SA and M-Scan Inc, and is also responsible for QA at all three laboratories.

spacer
Dr Fiona M Greer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze

Symbioze, the smart, high volume and sustainable on-body injector platform developed by Nemera, wins the ‘Connected Devices and Wearables’ Award at Pharmapack 2021 On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement